{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:19:45Z","timestamp":1787642385537,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T00:00:00Z","timestamp":1492819200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10157-017-1415-8","type":"journal-article","created":{"date-parts":[[2017,4,22]],"date-time":"2017-04-22T11:09:07Z","timestamp":1492859347000},"page":"110-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion"],"prefix":"10.1007","volume":"22","author":[{"given":"Mai","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,22]]},"reference":[{"issue":"26","key":"1415_CR1","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1056\/NEJMc063706","volume":"356","author":"A Bagga","year":"2007","unstructured":"Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid resistant nephrotic syndrome. N Engl J Med. 2007;356(26):2751\u20132. doi: 10.1056\/NEJMc063706 .","journal-title":"N Engl J Med"},{"issue":"8","key":"1415_CR2","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23(8):1269\u201379. doi: 10.1007\/s00467-008-0814-1 .","journal-title":"Pediatr Nephrol"},{"issue":"7","key":"1415_CR3","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24(7):1321\u20138. doi: 10.1007\/s00467-009-1191-0 .","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1415_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00467-015-3197-0","volume":"31","author":"K Kamei","year":"2016","unstructured":"Kamei K, Ogura M, Sato M, Sako M, Iijima K, Ito S. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol. 2016;31(1):89\u201395. doi: 10.1007\/s00467-015-3197-0 .","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"1415_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00467-014-2792-9","volume":"29","author":"M Sato","year":"2014","unstructured":"Sato M, Ito S, Ogura M, Kamei K. Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2014;29(8):1373\u20139. doi: 10.1007\/s00467-014-2792-9 .","journal-title":"Pediatr Nephrol"},{"issue":"9950","key":"1415_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384(9950):1273\u201381. doi: 10.1016\/S0140-6736(14)60541-9 .","journal-title":"Lancet"},{"issue":"6","key":"1415_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(6):1308\u201315. doi: 10.2215\/CJN.09421010 .","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1415_CR8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","volume":"27","author":"AL Sellier-Leclerc","year":"2012","unstructured":"Sellier-Leclerc AL, Baudouin V, Kwon T, et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow-up after CD19 recovery. Nephrol Dial Transplant. 2012;27(3):1083\u20139. doi: 10.1093\/ndt\/gfr405 .","journal-title":"Nephrol Dial Transplant"},{"key":"1415_CR9","doi-asserted-by":"crossref","unstructured":"ISKDC: The primary nephrotic syndrome in children. Identification of patients with minimal change nephrontic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. 1981;98(4):561\u20134.","DOI":"10.1016\/S0022-3476(81)80760-3"},{"issue":"11","key":"1415_CR10","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/acr.20279","volume":"62","author":"B Hugle","year":"2010","unstructured":"Hugle B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener\u2019s granulomatosis. Arthritis Care Res. 2010;62(11):1661\u20134. doi: 10.1002\/acr.20279 .","journal-title":"Arthritis Care Res."},{"issue":"3","key":"1415_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ki.1991.232","volume":"40","author":"A Koyama","year":"1991","unstructured":"Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 1991;40(3):453\u201360. doi: 10.1038\/ki.1991.232 .","journal-title":"Kidney Int"},{"issue":"1","key":"1415_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","volume":"122","author":"T Vallerskog","year":"2007","unstructured":"Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with S.L.E. Clin Immunol. 2007;122(1):62\u201374. doi: 10.1016\/j.clim.2006.08.016 .","journal-title":"Clin Immunol."},{"issue":"6","key":"1415_CR13","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00467-009-1119-8","volume":"24","author":"Y Hashimura","year":"2009","unstructured":"Hashimura Y, Nozu K, Kanda K, et al. Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Pediatr Nephrol. 2009;24(6):1181\u20136. doi: 10.1007\/s00467-009-1119-8 .","journal-title":"Pediatr Nephrol."},{"issue":"2","key":"1415_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.cyto.2014.12.028","volume":"72","author":"N Prasad","year":"2015","unstructured":"Prasad N, Jaiswal AK, Agarwal V, et al. Differential alteration in peripheral T-regulatory and T-effector cells with change in P-glycoprotein expression in childhood nephrotic syndrome: a longitudinal study. Cytokine. 2015;72(2):190\u20136. doi: 10.1016\/j.cyto.2014.12.028 .","journal-title":"Cytokine"},{"issue":"2","key":"1415_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/cei.12675","volume":"183","author":"R Bertelli","year":"2016","unstructured":"Bertelli R, Bonanni A, Di Donato A, Cioni M, Ravani P, Ghiggeri GM. Regulatory T cells and minimal change nephropathy: in the midst of a complex network. Clin Exp Immunol. 2016;183(2):166\u201374. doi: 10.1111\/cei.12675 .","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"1415_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","volume":"112","author":"R Stasi","year":"2008","unstructured":"Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood. 2008;112(4):1147\u201350. doi: 10.1182\/blood-2007-12-129262 .","journal-title":"Blood"},{"key":"1415_CR17","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar1954","volume":"8","author":"M Vigna-Perez","year":"2006","unstructured":"Vigna-Perez M, Hern\u00e1ndez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8:R83. doi: 10.1186\/ar1954 .","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"1415_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clim.2006.12.006","volume":"123","author":"PP Sfikakis","year":"2007","unstructured":"Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B-cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 2007;123(1):66\u201373. doi: 10.1016\/j.clim.2006.12.006 .","journal-title":"Clin Immunol."},{"issue":"11","key":"1415_CR19","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1182\/blood-2007-11-122713","volume":"111","author":"D Saadoun","year":"2008","unstructured":"Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral immune hemostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood. 2008;111(11):5334\u201341. doi: 10.1182\/blood-2007-11-122713 .","journal-title":"Blood"},{"issue":"2","key":"1415_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/art.20858","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52(2):501\u201313. doi: 10.1002\/art.20858 .","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1415_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/rheumatology\/keh443","volume":"44","author":"M Tokunaga","year":"2005","unstructured":"Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology. 2005;44(2):176\u201382. doi: 10.1093\/rheumatology\/keh443 .","journal-title":"Rheumatology"},{"issue":"7","key":"1415_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0091270005277075","volume":"45","author":"CM Ng","year":"2005","unstructured":"Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45(7):792\u2013801. doi: 10.1177\/0091270005277075 .","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1415_CR23","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1177\/0091270007305297","volume":"47","author":"F Breedveld","year":"2007","unstructured":"Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007;47(9):1119\u201328. doi: 10.1177\/0091270007305297 .","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"1415_CR24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-L\u00f3pez AJ, White CA, et al. Association of serum rituximab concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol. 1998;9(9):995\u20131001.","journal-title":"Ann Oncol"},{"key":"1415_CR25","doi-asserted-by":"publisher","unstructured":"Fujinaga S, Hirano D, Nishizaki N et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25(39):539\u20134. doi: 10.1007\/s00467-009-1377-5 .","DOI":"10.1007\/s00467-009-1377-5"},{"issue":"2","key":"1415_CR26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1600-6143.2006.01632.x","volume":"7","author":"EJ Ramos","year":"2007","unstructured":"Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant. 2007;7(2):402\u20137. doi: 10.1111\/j.1600-6143.2006.01632.x .","journal-title":"Am J Transplant"},{"key":"1415_CR27","doi-asserted-by":"publisher","unstructured":"Boumans MJ, Tak PP. Rituximab treatment in rheumatoid arthritis: How does it work? Arthritis Res Ther. 2009;11(6):134. doi: 10.1186\/ar2852 .","DOI":"10.1186\/ar2852"},{"issue":"6","key":"1415_CR28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","volume":"8","author":"V McDonald","year":"2010","unstructured":"McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201\u20138. doi: 10.1111\/j.1538-7836.2010.03818.x .","journal-title":"J Thromb Haemost"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-017-1415-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-017-1415-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-017-1415-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T12:47:57Z","timestamp":1569070077000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-017-1415-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,22]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["1415"],"URL":"https:\/\/doi.org\/10.1007\/s10157-017-1415-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,22]]}}}